Andres Poveda, MD Initia Oncology Hospital Quironsalud Valencia, Spain 5 Live #ASCO20

4:57

Key Insights on Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Ovarian Cancer
Andres Poveda, MD Initia Oncology Hospital Quironsalud Valencia, Spain 5 Live #ASCO20

Key Insights on Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Ovarian Cancer Similar Videos

Similar Videos